Earthwise Minerals appoints geologist Andy Randell to board
Bitget2026/10/08 12:08Earthwise Minerals appointed Andy Randell to its board. Randell previously served as a geological adviser, supporting the Iron Range Gold Project and broader exploration strategy. He has more than 20 years of mineral exploration experience, focusing on structural geology, project generation, and gold exploration. Randell is founder, CEO, chief geologist, and a director of Aeonian Resources. He is also founder and principal geoscientist of SGDS Hive, a geological consulting group formed in 2013. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Earthwise Minerals Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610080800ACCESSWRNAPR_____1234158) on October 08, 2026, and is solely responsible for the information contained therein.
- Earthwise Minerals appointed Andy Randell to its board.
- Randell previously served as a geological adviser, supporting the Iron Range Gold Project and broader exploration strategy.
- He has more than 20 years of mineral exploration experience, focusing on structural geology, project generation, and gold exploration.
- Randell is founder, CEO, chief geologist, and a director of Aeonian Resources.
- He is also founder and principal geoscientist of SGDS Hive, a geological consulting group formed in 2013.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
